Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccinationVaccination Published on 2023-09-302024-09-05 Journal: Multiple Sclerosis Journal [Category] update2024, [키워드] B-cell response Disease-modifying therapies multiple sclerosis SARS-CoV-2 vaccination sphingosine 1-phosphate receptor modulators T-cell Response [DOI] 10.1177/13524585231200719 PMC 바로가기 [Article Type] Vaccination
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trialClinical Trials and Therapeutics Published on 2022-06-282024-09-04 Journal: Multiple Sclerosis Journal [Category] 대상포진, [키워드] adverse events Clinical efficacy extension study multiple sclerosis Ozanimod sphingosine 1-phosphate receptor modulators [DOI] 10.1177/13524585221102584 PMC 바로가기 [Article Type] Clinical Trials and Therapeutics